The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.
Taro Pharmaceuticals Inc., the Canadian subsidiary of Taro Pharmaceutical Industries, based in Haifa Bay, Israel, is investing $247 million in new manufacturing and R&D equipment to expand research and production at its facility...
Novartis has received FDA approval for its new molecular entity, Zykadia (ceritinib), for treating patients with a certain type of late-stage (metastatic) non-small cell lung cancer (NSCLC). Zykadia is an oral anaplastic lymphoma kinase...
Takeda Pharmaceutical Company Limited has been selected by the Japanese government to receive a 7.2 billion yen ($70.5 million) supplemental subsidy to expand production capacity for pandemic influenza vaccines at its plant in Hikari...
The pharmaceutical companies Lupin Limited, headquartered in Mumbai, India, and Yoshindo Inc., based in Toyama, Japan have formed a strategic joint venture agreement to create a new entity, YL Biologics (YLB). YLB will be...
Bristol-Myers Squibb Company has acquired iPierian, a privately held biotechnology company focused on the discovery and development of new treatments for Tauopathies, a class of neurodegenerative diseases associated with the pathological...
Pfizer Inc. confirmed on April 28, 2014 of its interest in a possible merger transaction with AstraZeneca despite AstraZeneca's assertion that it wishes to remain an independent company. Pfizer Chairman and CEO Ian Read outlined...
Forest Laboratories, Inc. has agreed to acquire Furiex Pharmaceuticals, a drug development collaboration company, for $95 per share, or approximately $1.1 billion in cash, and up to $30 per share (approximately $360 million in...
Hydra Biosciences, Inc., a privately-held biopharmaceutical company based in Cambridge, Massachusetts, which is developing drugs to treat pain, inflammation, anxiety, and other diseases using novel ion channels, and Boehringer...
The biopharmaceutical company Hyperion Therapeutics has agreed to acquire Andromeda Biotech Ltd., an Israel-based subsidiary of Clal Biotechnology Industries Ltd. Andromeda is focused on the development of DiaPep277®, an immune intervention...
Celgene Corporation has entered into a global license agreement with Nogra Pharma Limited, a private pharmaceutical company based in Dublin, Ireland, to develop and commercialize GED-0301, an oral antisense DNA oligonucleotide targeting Smad7...
Actavis plc reports that G. Frederick Wilkinson , President, Actavis Global R&D, will leave the company effective April 25, 2014. Wilkinson has accepted the position of President and Chief Executive Officer at the specialty pharmaceutical...
Actavis plc has entered into an agreement with Pfizer, Inc. to settle all outstanding patent litigation related to Actavis' generic version of Celebrex® (celecoxib) 50-mg, 100-mg, 200-mg and 400-mg capsules. Celebrex® is indicated for the...
Novartis has announced that it has created a shared services organization, Novartis Business Services (NBS), which will consolidate a number of business support services, including procurement. The move, part of an ongoing productivity...
Aastrom Biosciences, Inc., a developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, has agreed to acquire Sanofi's Cell Therapy and Regenerative Medicine (CRTM) business...
FDA has approved Sylvant (siltuximab) to treat patients with multicentric Castleman's disease (MCD), a rare disorder similar to lymphoma (cancer of the lymph nodes). Sylvant is marketed by Janssen Biotech Inc., based in Horsham,...
